Extent of Pharmacotherapy in Covid-19: An Observational Study in a Dedicated Hospital in Bangladesh
Objective: With the rapid increase in the rate of infection, repurposing use of many drugs like antivirals, antibiotics, LMWH, steroid, oxygen therapy were considered as an option to find promising anti-COVID therapeutics. In this study, we aim to observe the extent and variety of drugs used in different clinical categories of COVID-19 patients admitted to hospital in Bangladesh. To observe the requirement of oxygen therapy according to severity was also a prime objective to reveal the overall trend, frequency, and pattern of pharmacotherapy in a COVID-dedicated hospital.
Materials and method: A total of 1348 patients were admitted, of whom 473 were included in this single-center retrospective study. The critical group consists of 99 ICU patients, the severe group has 38, moderate was 82 and mild group 254 cases, admitted in the general ward. Hospital records of each patient were screened and information about drug and supportive therapy were collected manually by the researchers in the data collection sheet. Data express in MS excel spreadsheet and result expressed in percentage.
Results: Critical group received remdesivir (85.86%), favipiravir (27.28%), meropenem (92.93%), moxifloxacin (87.88%) dexamethasone (41.48%), Low Molecular Weight Heparin (98.99%). They also received supportive O2 therapy like High Flow Nasal Cannula (67.68%), Non-Invasive Ventilation (26.67%), and mechanical ventilator (6.06%). A severe group of patients receives the same group of drugs 97.27%, 5.26%, 60.53%, 47.37%, methylprednisolone (55.26%), and 100% LMWH. A moderate group of the patient received favipiravir (97.56%), cephalosporin (64.67%), LMWH (89.02%) and low flow O2 (97.36%) in a higher percentage. All patients of the mild group received doxycycline, ivermectin. Total 33 patients transfuse convalescent plasma.
Conclusion: Antiviral, broad-spectrum antibiotics, anti-protozoal, LMWH, corticosteroid, and oxygen therapy are the available treatment option against different clinical categories of admitted COVID-19 patients.
Keywords: COVID-19, antiviral, antibiotic, steroid, O2 therapy
2. Estimating mortality from COVID-19. World Health Organization, 4th august,2020 [Available at https://www.who.int/new-rom/commentaries/detail/estimatin-mortality-from-covid-1]
3. World Metrics. COVID-19 coronavirus outbreak: World Metrics; 17th December, 2020 [Available from: https://www.worldometers.info/coronavirus/country/bangladesh/]
4. COVID- 19 pandemic in South Asia. 19th October, 2020 [Available at https://www.en.m.wikipedia.org/]
5. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382(8):727–3.doi: https://www.nejm.org/doi/10.1056/NEJMoa2001017
6. Fan C, Li K, Ding Y, et al. ACE2 expression in kidney and testis may cause kidney and testis damage after 2019-nCoV infection. Med Rxiv; 2020. doi: https://doi.org/10.1101/2020.02.12.20022418
7. Mahallawi WH, Khabour OF, Zhang Q, et al. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018; 104: 8–13. DOI: 10.1016/j.cyto.2018.01.025 https://pubmed.ncbi.nlm.nih.gov/29414327/
8. Perveen RA, Nasir M, Talha KA, Selina F, Islam MA. Systemic Review on Current Antiviral Therapy in COVID-19 Pandemic. Med J Malaysia. 2020 Nov; 75 (6): 615-621. https://pubmed.ncbi.nlm.nih.gov/33219182/
9. Novel Coronavirus (COVID-19) Guidelines. Bangladesh. 5th November, 2020. https://dghs.gov.bd/index.php/en/home/5376-novel-coronavirus-covid-19-guidelines
10. Nasir M, Talha KA, Islam T, Saha SK, Selina F, Parveen RA. Use of Remdesivir in the Management of COVID-19: A Systematic Review on Current Evidences. Mymensingh Med J. 2020 Apr; 29(2):481-487. PMID: 32506110.
11. Wang D, Hu B, Hu C, et al. JAMA. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. https://jamanetwork.com/journals/jama/fullarticle/2761044
12. Saha A, Ahsan MM, Quader T, et al. Characteristics, Management and Outcome of Critically ill COVID-19 Patients admitted to ICU in hospitals in Bangladesh: A retrospective Study. medRxiv. 2020. https://doi.org/10.1101/2020.09.24.20201285
13. Hossain I, Khan MH, Tuhin SG, et al, Baseline characteristics, level of disease severity and outcomes of patients with COVID-19 admitted to intensive care unit in COVID-19 dedicated Mugda Medical College and Hospital, Dhaka, Bangladesh. Int J Community Med Public Health. 2020; 7(10): 3837-3842. DOI: http://dx.doi.org/10.18203/2394-6040.ijcmph20204347.
14. Zhang G, Hu C, Luo L, et al. Clinical feature and short-term outcome of 221 patients with COVID-19 in Wuhan, China. J ClinVirol. 2020. DOI: 10.1016/j.jcv.2020.104364. https://pubmed.ncbi.nlm.nih.gov/32311650/
15. Grasselli G, et al., Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. The journal of the American medical association, 2020. 323(16):1574-1581. doi:10.1001/jama.2020.5394 https://jamanetwork.com/journals/jama/fullarticle/2764365
16. Wang Y, Zhang D, Du G et al. Remdesivir in adults with severe COVID-19: a randomised,double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395 (10236):1569-1578. DOI: https://doi.org/10.1016/S0140-6736(20)31022-9https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext
17. Cai Q, Huang D, Yu H, et al. COVID-19: Abnormal liver function tests. J. Hepatol. 2020; 73(3):566-574. DOI: https://doi.org/10.1016/j.jhep.2020.04.006
18. Nasir M, Perveen RA, Saha SK, Talha KA, Selina F, Islam MA. Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2. Mymensingh Med J. 2020 Jul;29(3):747-754. PMID: 32844821. https://pubmed.ncbi.nlm.nih.gov/32844821/
19. Islam QT, Hossain HT, Fahim FR, Rashid MU. Clinico-demographic profile, treatment outline and clinical outcome of 236 confirmed hospitalized COVID-19 patients: A Multicentered descriptive study in Dhaka, Bangladesh. BJM. 2020; 31(2):52- 57. DOI: https://doi.org/10.3329/bjm.v31i2.48532https://www.banglajol.info/index.php/BJMED/article/view/48532
20. Million M, Lagier J-C, Gautret P, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis 2020. 101738. DOI: 10.1016/j.tmaid.2020.101738 https://pubmed.ncbi.nlm.nih.gov/32387409/
21. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020;39(6):1059–1061. DOI:10.1007/s10096-020-03913-9 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185831/
22. Bhuyan MAR, Al Mahtab M, Ashab E, et al. Treatment of COVID-19 Patients at a Medical College Hospital in Bangladesh. Euroasian J Hepato-Gastroenterol 2020; 10(1):27–30. doi:10.5005/jp-journals-10018-1317. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376594/
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).